Literature DB >> 24046371

Tumor suppressor p16INK4A is necessary for survival of cervical carcinoma cell lines.

Margaret E McLaughlin-Drubin1, Donglim Park, Karl Munger.   

Abstract

The tumor suppressor p16(INK4A) inhibits formation of enzymatically active complexes of cyclin-dependent kinases 4 and 6 (CDK4/6) with D-type cyclins. Oncogenic stress induces p16(INK4A) expression, which in turn triggers cellular senescence through activation of the retinoblastoma tumor suppressor. Subversion of oncogene-induced senescence is a key step during cancer development, and many tumors have lost p16(INK4A) activity by mutation or epigenetic silencing. Human papillomavirus (HPV)-associated tumors express high levels of p16(INK4A) in response to E7 oncoprotein expression. Induction of p16(INK4A) expression is not a consequence of retinoblastoma tumor suppressor inactivation but is triggered by a cellular senescence response and is mediated by epigenetic derepression through the H3K27-specific demethylase (KDM)6B. HPV E7 expression causes an acute dependence on KDM6B expression for cell survival. The p16(INK4A) tumor suppressor is a critical KDM6B downstream transcriptional target and its expression is critical for cell survival. This oncogenic p16(INK4A) activity depends on inhibition of CDK4/CDK6, suggesting that in cervical cancer cells where retinoblastoma tumor suppressor is inactivated, CDK4/CDK6 activity needs to be inhibited in order for cells to survive. Finally, we note that HPV E7 expression creates a unique cellular vulnerability to small-molecule KDM6A/B inhibitors.

Entities:  

Keywords:  apoptosis; biomarker; cancer therapy; synthetic lethality

Mesh:

Substances:

Year:  2013        PMID: 24046371      PMCID: PMC3791710          DOI: 10.1073/pnas.1310432110

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  47 in total

1.  Degradation of the retinoblastoma tumor suppressor by the human papillomavirus type 16 E7 oncoprotein is important for functional inactivation and is separable from proteasomal degradation of E7.

Authors:  S L Gonzalez; M Stremlau; X He; J R Basile; K Münger
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

2.  Short hairpin RNA system to inhibit human p16 in squamous cell carcinoma.

Authors:  Jennifer J Shin; Takafumi Katayama; William A Michaud; James W Rocco
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2004-01

Review 3.  Polycomb silencing mechanisms and the management of genomic programmes.

Authors:  Yuri B Schwartz; Vincenzo Pirrotta
Journal:  Nat Rev Genet       Date:  2007-01       Impact factor: 53.242

Review 4.  To cycle or not to cycle: a critical decision in cancer.

Authors:  M Malumbres; M Barbacid
Journal:  Nat Rev Cancer       Date:  2001-12       Impact factor: 60.716

5.  A novel nuclear protein, 5qNCA (LOC51780) is a candidate for the myeloid leukemia tumor suppressor gene on chromosome 5 band q31.

Authors:  Z Hu; I Gomes; S K Horrigan; J Kravarusic; B Mar; Z Arbieva; B Chyna; N Fulton; S Edassery; A Raza; C A Westbrook
Journal:  Oncogene       Date:  2001-10-18       Impact factor: 9.867

6.  Alterations in the p16/pRb cell cycle checkpoint occur commonly in primary and metastatic human prostate cancer.

Authors:  David F Jarrard; Joshua Modder; Paul Fadden; Vivian Fu; Linda Sebree; Dennis Heisey; Steven R Schwarze; Andreas Friedl
Journal:  Cancer Lett       Date:  2002-11-28       Impact factor: 8.679

7.  Role of histone H3 lysine 27 methylation in X inactivation.

Authors:  Kathrin Plath; Jia Fang; Susanna K Mlynarczyk-Evans; Ru Cao; Kathleen A Worringer; Hengbin Wang; Cecile C de la Cruz; Arie P Otte; Barbara Panning; Yi Zhang
Journal:  Science       Date:  2003-03-20       Impact factor: 47.728

8.  Cyclin-dependent kinases regulate the antiproliferative function of Smads.

Authors:  Isao Matsuura; Natalia G Denissova; Guannan Wang; Dongming He; Jianyin Long; Fang Liu
Journal:  Nature       Date:  2004-07-08       Impact factor: 49.962

Review 9.  Epigenetics and cancer.

Authors:  Anders H Lund; Maarten van Lohuizen
Journal:  Genes Dev       Date:  2004-10-01       Impact factor: 11.361

Review 10.  Role of cell-cycle regulatory proteins in gynecological cancer.

Authors:  Karin Milde-Langosch; Sabine Riethdorf
Journal:  J Cell Physiol       Date:  2003-08       Impact factor: 6.384

View more
  65 in total

Review 1.  Prevalence of Human Papillomavirus in Oropharyngeal Cancer: A Systematic Review.

Authors:  Andrew P Stein; Sandeep Saha; Jennifer L Kraninger; Adam D Swick; Menggang Yu; Paul F Lambert; Randall J Kimple
Journal:  Cancer J       Date:  2015 May-Jun       Impact factor: 3.360

2.  Human papillomavirus type 16 E7 oncoprotein upregulates the retinoic acid receptor-beta expression in cervical cancer cell lines and K14E7 transgenic mice.

Authors:  Jorge Gutiérrez; Enrique García-Villa; Rodolfo Ocadiz-Delgado; Enoc M Cortés-Malagón; Juan Vázquez; Alejandra Roman-Rosales; Elizabeth Alvarez-Rios; Haydar Celik; Marta C Romano; Aykut Üren; Paul F Lambert; Patricio Gariglio
Journal:  Mol Cell Biochem       Date:  2015-07-15       Impact factor: 3.396

3.  Cellular signaling in sinecatechins-treated external genital and perianal warts: unraveling the mechanism of action of a botanical therapy.

Authors:  Harrison P Nguyen; Hung Q Doan; Peter Rady; Stephen K Tyring
Journal:  Virol Sin       Date:  2015-06       Impact factor: 4.327

Review 4.  The human papillomavirus E7 oncoprotein as a regulator of transcription.

Authors:  William K Songock; Seong-Man Kim; Jason M Bodily
Journal:  Virus Res       Date:  2016-11-08       Impact factor: 3.303

Review 5.  Epigenetics and cervical cancer: from pathogenesis to therapy.

Authors:  Jinchuan Fang; Hai Zhang; Sufang Jin
Journal:  Tumour Biol       Date:  2014-02-20

Review 6.  [HPV-associated oropharyngeal cancer-incidence, trends, diagnosis, and treatment].

Authors:  S Wagner; H Reder; S J Sharma; N Würdemann; C Wittekindt; J P Klußmann
Journal:  Urologe A       Date:  2018-12       Impact factor: 0.639

7.  Inhibition of enhancer of zeste homolog 2 increases the expression of p16 and suppresses the proliferation and migration of ovarian carcinoma cells in vitro and in vivo.

Authors:  Fangfang Lu; Hong Xu; Qi Wang; Meiyi Li; Jiahua Meng; Yan Kuang
Journal:  Oncol Lett       Date:  2017-12-28       Impact factor: 2.967

Review 8.  The role of high-risk human papillomavirus infections in laryngeal squamous cell carcinoma.

Authors:  Claus Wittekindt; Nora Wuerdemann; Stefan Gattenlöhner; Alexander Brobeil; Malgorzata Wierzbicka; Steffen Wagner; Jens Peter Klußmann
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-08-31       Impact factor: 2.503

Review 9.  Impact of Replication Stress in Human Papillomavirus Pathogenesis.

Authors:  Cary A Moody
Journal:  J Virol       Date:  2019-01-04       Impact factor: 5.103

10.  Meta-analysis of survival in patients with HNSCC discriminates risk depending on combined HPV and p16 status.

Authors:  Annekatrin Coordes; Klaus Lenz; Xu Qian; Minoo Lenarz; Andreas M Kaufmann; Andreas E Albers
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-07-31       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.